SOURCE: Pharming Group N.V.

December 02, 2010 04:30 ET

Pharming awarded 'Best Biotechnology Company' by the World Technology Network

LEIDEN, NETHERLANDS--(Marketwire - December 2, 2010) - Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that last night it received the Award for Best Biotechnology Company for 2010 by the World Technology Network (WTN) at the World Technology Summit (November 30-December 1, 2010) in New York City. Pharming has been awarded for its innovative work on production of life enhancing drugs derived from its transgenic platform, an achievement viewed by the voting committee as one of the greatest likely long-term significant achievements within the science and technology arena.

The World Technology Awards are presented annually by the WTN at a dinner of its World Technology Summit to individuals and corporations achieving significant, lasting progress in categories pertaining to science, technology, finance, IT, design, and many more. The first World Technology Summit and Awards took place on November 12, 1999 in London. Last night's Awards dinner was held at the Time Life Building in Manhattan and the awards are presented in association with Time, NASDAQ, Fortune, AAAS, Science, NYAS, and The Technology Review.

Sijmen de Vries, Pharming's CEO, said, "This has been a highly significant year for Pharming with the European approval of our lead product Ruconest for treatment of acute attacks of Hereditary Angioedema. This highly innovative product is produced through Pharming's proprietary transgenic technology and will be launched this year. Ruconest has been in clinical development with the needs of patients at the forefront of our drive to get this to market. We are delighted to accept this award on behalf of the entire Pharming team as recognition for their commitment and hard work."

Previous winners have included Alnylam, Advanced Cell Technology, Amyris Biotechnologies, Genencor International, Genentech, International Rice Genome Sequencing Project.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest™ (Rhucin® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.


[HUG#1467947]


Press release (PDF): http://hugin.info/132866/R/1467947/405594.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Pharming Group N.V. via Thomson Reuters ONE

Contact Information

  • Contact:
    Marjolein van Helmond
    T: +31 (0)71 52 47 431
    or +31 (0)6 109 299 54